医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

New Frontier Health to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on March 26, 2020

2020年03月18日 PM09:30
このエントリーをはてなブックマークに追加


 

BEIJING

New Frontier Health Corporation (“NFH” or “the Company”) (NYSE: NFH), operator of the premium healthcare services provider United Family Healthcare (UFH), today announced that it plans to release its fourth quarter and fiscal year ended December 31, 2019, financial results before the U.S. market opens on Thursday, March 26, 2020.

The Company will hold a conference call on Thursday, March 26, 2020, at 8:00 am Eastern Time (or Thursday, March 26, 2020, at 8:00 pm Beijing Time) to discuss the financial results. Participants may access the call by dialing the following numbers:

United States: 1-888-204-4368
International: 1-720-543-0214
China Domestic: 400 120 8590
Hong Kong: 800 961 384
Conference ID: 6225395

The replay will be accessible through April 2, 2020, by dialing the following numbers:

United States: 1-844-512-2921
International: 1-412-317-6671
Conference ID: 6225395

The webcast will be available at www.nfh.com.cn and will be archived on the site shortly after the call has concluded.

About New Frontier Health Corporation

New Frontier Health Corporation (NYSE: NFH) is the operator of United Family Healthcare (UFH), a leading private healthcare provider offering comprehensive premium healthcare services in China through a network of private hospitals and affiliated ambulatory clinics. UFH currently has nine hospitals and in total in operation or under construction in all four 1st tier cities and selected 2nd tier cities. Additional information may be found at www.nfh.com.cn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005188/en/

CONTACT

Media

Harry Chang

Tel: +852-9822-1806

Email: harry@new-frontier.com

Wenjing Liu

Tel: +86-186-1151-5796

Email: liu.wenjing@ufh.com.cn

Investors

ICR, LLC

William Zima/Rose Zu

Tel: +1-203-682-8200

Email: bill.zima@icrinc.com/rose.zu@icrinc.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 3 Factors Contribute to Taiwan’s Success Against COVID-19: Former VP
  • New Interim Results from Phase IIIb Study Reinforce the Long-Term Safety Profile of Chugai’s Hemlibra in Hemophilia A
  • COVID-19ウイルスに対するBETADINE®殺菌剤製品の有効性を裏付けるラボ研究
  • Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders
  • 武田薬品とニューヨーク科学アカデミーが2020年Innovators in Science Awardの受賞者を発表